Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 160,158 shares at $2.34 ($375K) on 2022-03-16, disclosed to the SEC on 2022-03-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.34 | 80,079 | $187K | 50.0% |
| 2 | $2.34 | 80,079 | $187K | 50.0% |
| Total | $2.34 avg | 160,158 | $375K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |
| AGLE | BUY | 2020-05-04 | $784K | — | Filing → |